肝硬化患者家庭使用非选择性β受体阻滞剂与感染相关住院风险降低相关
一项病例对照研究纳入2165例肝硬化患者,评估家庭使用非选择性β受体阻滞剂(NSBB)与感染相关住院的关系。倾向性评分匹配分析显示,家庭使用NSBB与总体及特定感染风险降低相关,未使用NSBB者感染、自发性细菌性腹膜炎和菌血症的比值比分别为2.5、4.0和6.0。
要点
- 肝硬化患者家庭使用NSBB与感染相关住院风险降低相关。
- 未使用NSBB者感染OR=2.5,SBP OR=4.0,菌血症OR=6.0。
- NSBB用于一级或二级食管静脉曲张预防或其他指征时效果相似。
核心结论
- 肝硬化患者家庭使用NSBB与感染相关住院减少相关,提示NSBB可能降低该人群感染风险。
研究设计与样本
- 病例对照研究,纳入2011年1月1日至2016年12月31日期间首次住院的肝硬化患者,共2165例符合标准。
- 采用倾向性评分匹配分析比较使用与未使用NSBB的患者,计算比值比。
主要发现
- 感染发生于33%的住院入院中。
- 倾向性评分匹配队列中,家庭使用NSBB与总体及特定感染风险降低相关。
- 未使用NSBB者感染OR=2.5,自发性细菌性腹膜炎OR=4.0,菌血症OR=6.0。
- NSBB用于一级或二级食管静脉曲张预防或其他指征时效果相似。
关键数值与推荐
- 入组患者平均MELD评分12±1,Charlson合并症指数4±2,Child-Pugh评分8±2。
- 腹水是最常见的门脉高压并发症(44%),23%的患者在家使用NSBB。
临床怎么用
- 对于肝硬化患者,家庭使用NSBB可能与减少感染相关住院有关,但需结合个体情况评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-selective beta-blockers (NSBBs) reduce enteric bacterial translocation rates and the frequency of spontaneous bacterial peritonitis (SBP) in animal models. AIM: To evaluate the effect of NSBBs on infection-related admissions. METHODS: We performed a case-control study of cirrhotic patients' first in-patient admission between 1 January 2011 and 31 December 2016. We examined NSBB use and the development of infection. We performed a propensity score-matched analysis in those with NSBB use vs no use and calculated odds ratios on this matched cohort to determine the odds of outcomes based on NSBB use. RESULTS: We identified 2165 cirrhotic patients who met our inclusion criteria. Most patients were Caucasian (69%), male (62%). Admission Model for End stage Liver Disease (MELD) score, Charlson comorbidity index and Child-Pugh score were 12 ± 1, 4 ± 2, and 8 ± 2, respectively. Ascites was the most common complication of portal hypertension (44%); 23% of patients used NSBBs at home. Infections occurred in 33% of admissions. In the propensity score-matched cohort, the use of NSBBs at home was associated with lower overall, and specific, infections. The effect was similar in patients taking NSBBs for either primary or secondary oesophageal variceal prophylaxis and for those on NSBBs for other indications. Patients not on NSBBs had higher odds of infection (OR = 2.5), SBP (OR = 4.0), and bacteraemia (OR = 6.0). CONCLUSION: Home use of NSBBs by patients with cirrhosis was associated with fewer infection-related admissions. The data suggest that NSBBs in this group of patients reduce the risk of infection.
引用
- Sasso R, Rockey DC. Non-selective beta-blocker use in cirrhotic patients is associated with a reduced likelihood of hospitalisation for infection. Aliment Pharmacol Ther. 2020. PMID: 33314175. doi:10.1111/apt.16156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。